EU-certified medical vaporizers enter the market: setting a new regulatory standard.

The race for relevance in the global cannabis community has taken a new turn with the introduction of medically registered handheld vape batteries and cartridges. Only a few cannabis markets, such as Australia and the U.K., have clearly accepted non-medically certified oil vaporizer equipment, and to some extent Germany has as well. The rest of the global medical cannabis markets have not reached that far in their acceptance of non-medical vaporizer units, with the exception of a few daring compound pharmacists in Poland and other small adventurous groups.

Regulators, industry insiders, and patients will now be offered medically certified oil vaporizers, based on IP developed by Jupiter Research. This is no longer just a rumor or a tale told by many, but a reality.

A key difference between a medically certified oil vaporizer and a non-medically approved one lies in their regulatory standard. Non-medical units are often consumer-grade devices designed without stringent oversight of materials, manufacturing, or long-term product stability. In contrast, medically certified vaporizers must meet the same rigorous requirements as other pharmaceutical equipment. This includes using medical-grade materials, meeting biological testing standards such as 10993 and 18562, and demonstrating that the device delivers a consistent dose of medicine over its entire lifespan. This provides a crucial level of assurance for doctors, pharmacists, and insurance companies that is absent with uncertified consumer devices.

A New Regulatory Standard

The first two medically certified handheld oil devices are about to hit the global markets. These two devices, developed in partnership with Jupiter Research, are similar offerings but differ in respect to some functionality for the medical patient, such as haptic feedback and ergonomic design, and the vaporizer cartridges. We will focus on our offering with Airo, and SOMAI’s EU-GMP products which have gone through rigorous and lengthy testing requirements to perfect and deliver our line of vaporizer cartridges with long-term stability.

Compound pharmacies can produce products quickly because they are not required to follow the same strict manufacturing regulations and processes. They automatically receive three months of stability certification due to their process and the pharmacist’s assessment. EU-GMP, on the other hand, has much higher requirements and requires long-term stability. EU-GMP products take roughly two and a half years to procure equipment, get through stability testing, and have regulators approve the format. To date, there is only one EU-GMP manufactured vaporizer on the market.

The Airo Brands /Somaí Partnership: A True EU-GMP Offering

The second launch coming to market is the Airo Brands Medical Inhalation System through Somaí Pharmaceuticals, which is being launched in multiple countries as an EU-GMP finished dosage with a long shelf life. Airo Brands is well-known in U.S Market as a leading vaporizer company. Their terpene vault is known for producing the most coveted tastes and effects in the entire industry.

Airo Brands has teamed up with Somaí Pharmaceuticals to bring a true EU-GMP offering of the medical battery and the medically filled EU-GMP cartridge. This robust offering provides a medically certified and approved product to the market because the rigorous standards of EU-GMP manufacturing and stability have been applied. Many of Somaí Pharmaceuticals’ vapes are even close to two years of stability. Airo Brands is already working on a next-generation battery and cartridge, while Somaí is working on other cartridge offerings. Expect multiple offerings from the Airo Brands/Somaí teams as they change the face of medical vaporizers with U.S. know-how.

The Future of Medical Vapes

The race is on, no matter how the global community looks at this. We expect in the coming year(s) more groups will increasingly apply for medical vaporizer certification. You can be certain that the largest groups in the world want to tap into the global medical markets. Most people agree that Europe and other world markets will embrace medical rules for cannabis for the foreseeable future, and that recreational rules will likely not be adopted for decades, if ever. Equipment like vaporizers will be required. There is even a possibility that once regulators in the U.K. and Australia understand that there is a medical device available, they will require all oil vaporizers to be medical devices.

These launches are significant because for the first time, regulators, doctors, pharmacists, and insurance companies will be able to get behind the medical equipment certification of a battery and cartridge combination. This will change how the global medical markets talk about quality and compliance. Doctors in hard-to-navigate countries looking for an alternative to the fast absorption of flower now have a globally certified standard they can accept. Although the future is hard to predict, the race is surely on since vaporizers are a multi-billion-dollar market that just received official medical certification.

____________________________________________________________________________________________________

____________________________________________________________________________________________________

What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

SOMAÍ Pharmaceuticals

More postsBio

SOMAÍ is a leading, vertically integrated company with operations in several countries (MCO), with a global presence in the distribution of the largest and most advanced portfolio of pharmaceutical extracts and flowers containing cannabinoids, both certified by EU Good Manufacturing Practices (EU-GMP).

SOMAÍ has a modern production unit, SOMAÍ Pharmaceuticals, and an indoor cannabis plantation, NovaSoma, in Lisbon, Portugal, as well as global sales teams in the largest medicinal cannabis markets. We continue to make global acquisitions and partnerships with brands, making us one of the few and first vertically integrated companies headquartered in the EU, capable of meeting the diverse needs of the rapidly growing global cannabis markets.

This author does not have any more posts.